BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36047093)

  • 1. Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
    Suichi T; Misawa S; Sekiguchi Y; Shibuya K; Nakamura K; Kano H; Aotsuka Y; Otani R; Morooka M; Tsukamoto S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Kuwabara S
    Intern Med; 2022; 61(17):2567-2572. PubMed ID: 36047093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.
    Li J; Huang XF; Cai QQ; Wang C; Cai H; Zhao H; Zhang L; Cao XX; Gale RP; Zhou DB
    Am J Hematol; 2018 Jun; 93(6):803-809. PubMed ID: 29603764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone.
    Gao Y; Zhang S; Yang L; Li J; Liu Y; Wang T
    Front Immunol; 2021; 12():681360. PubMed ID: 34025681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy.
    He T; Zhao A; Zhao H; Cai H; Feng J; Zhang L; Cao X; Zhou D; Li J
    Ann Hematol; 2019 Mar; 98(3):735-743. PubMed ID: 30612232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review.
    Khouri J; Nakashima M; Wong S
    JAMA Oncol; 2021 Sep; 7(9):1383-1391. PubMed ID: 34081097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.
    Suichi T; Misawa S; Nagashima K; Sato Y; Iwai Y; Katayama K; Sekiguchi Y; Shibuya K; Amino H; Suzuki YI; Tsuneyama A; Nakamura K; Kuwabara S
    Intern Med; 2020 May; 59(9):1149-1153. PubMed ID: 32009091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of POEMS syndrome with lenalidomide and dexamethasone].
    Goto A; Iyama S; Sugama Y; Yoshida M; Ibata S; Tatekoshi A; Fujita C; Kikuchi S; Ikeda H; Murase K; Takada K; Kato J; Kobune M
    Rinsho Ketsueki; 2019; 60(4):308-313. PubMed ID: 31068561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.
    Taenaka R; Shimokawa S; Katayama A; Nagao T; Obara T; Nishimura N; Tsujimoto A; Kohno K; Aoki K; Ogawa R
    J Med Case Rep; 2022 Aug; 16(1):311. PubMed ID: 35978379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical revascularization for quasi-moyamoya disease associated with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome: a case report and literature review.
    Kubota Y; Hanaoka Y; Koyama JI; Takahashi Y; Katoh N; Iwaya M; Fujii Y; Ogiwara T; Horiuchi T
    Nagoya J Med Sci; 2023 Feb; 85(1):141-149. PubMed ID: 36923610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Living with Polyneuropathy Organomegaly Endocrinopathy Monoclonal gammopathy Skin changes (POEMS) syndrome: a case study of healthcare experiences and quality of life.
    Twigg J; Methley A; Lavin T; Dickinson G; Teager A
    Disabil Rehabil; 2021 Aug; 43(17):2502-2510. PubMed ID: 31838877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide and Dexamethasone for a Patient of POEMS Syndrome Presenting with Massive Ascites.
    Ueda S; Yonemoto S; Oka K; Fujii N; Nakata K; Matsunaga H; Kataoka S; Iwama Y; Narahara H; Yasunaga Y; Inui Y; Kawata S
    Case Rep Hematol; 2014; 2014():818946. PubMed ID: 24782932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in choroidal vascular structures due to serum levels of vascular endothelial growth factor in patients with POEMS syndrome.
    Yokouchi H; Nagasato D; Mitamura Y; Egawa M; Tabuchi H; Misawa S; Kuwabara S; Baba T
    Sci Rep; 2023 Jun; 13(1):10650. PubMed ID: 37391497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ixazomib-Based Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in the Treatment of POEMS Syndrome].
    Cheng P; Wang LL; Guan J; Zhou Y; Wang QX; Cheng H; Zou L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):937-942. PubMed ID: 35680830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POEMS Syndrome with Biclonal Gammopathy and Renal Involvement.
    Inoue K; Nagai K; Tsukada T; Iwase M; Sakata A; Ueda A; Yamagata K
    Intern Med; 2022 Jul; 61(14):2191-2196. PubMed ID: 35283379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.
    Nozza A; Terenghi F; Gallia F; Adami F; Briani C; Merlini G; Giordano L; Santoro A; Nobile-Orazio E
    Br J Haematol; 2017 Dec; 179(5):748-755. PubMed ID: 29048107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability of optic disc edema area in estimating the severity of papilledema in patients with POEMS syndrome.
    Liu LS; Zhang X; Zhao H; Gao XM; Zhou DB; Dai RP; Li J
    Orphanet J Rare Dis; 2020 May; 15(1):116. PubMed ID: 32429967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
    Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
    Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome.
    Gao XM; Yu YY; Zhao H; Cai H; Zhang L; Cao XX; Zhou DB; Li J
    Ann Hematol; 2021 Nov; 100(11):2755-2761. PubMed ID: 34331562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rapid improvement of fluid retention with lenalidomide plus low-dose dexamethasone for POEMS syndrome relapsed after autologous peripheral blood stem cell transplantation].
    Ohashi K; Yokoyama A; Kagoo T; Hosoda T; Yamamoto R; Yoneda M; Kudo M; Boku S; Ueno H; Yano T
    Rinsho Ketsueki; 2013 Jul; 54(7):670-4. PubMed ID: 23912352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.